HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SlimFast ‘Clinically Proven’ Claim Based On Discontinued Products, NAD Review Finds

Executive Summary

Glanbia subsidiary marketing SlimFast plans to appeal National Advertising Division decision, following a challenge by Atkins marketer Simply Good, finding a “clinically proven” packaging claim based on evidence from discontinued products isn’t substantiated.

You may also be interested in...



SlimFast ‘Clinically Proven’ Claim Needs Focus, BBB National Programs’ Appeals Board Agrees

SlimFast Foods agrees to comply with National Advertising Review Board’s conclusions but says it disagrees that packaging and labeling for its products doesn’t make clear that “clinically proven” references entire plans.

Vitafusion ‘Clinically Proven Absorption’ Claim Fails In C&D Appeal Of Industry Self-Regulation Review

Church & Dwight will comply with National Advertising Review Board decision to discontinue claim for vitafusion supplements. The panel rejected C&D’s argument that any amount of vitamin absorption is “clinically meaningful” and deferred to the National Advertising Division on C&D’s procedural challenge.

Health, Beauty And Wellness Transaction News: SlimFast To Glanbia, More MedMen Moves, Empower Production Partner

Glanbia adds SlimFast to its lineup; MedMen making moves in cannabis market; and production partner for Empower medical cannabis.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151763

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel